# EDGAR Filing Document

**Accession Number:** 0001604924
**File Stem:** 0001171843-23-000264
**Filing Date:** 2023-1
**Character Count:** 2904
**Document Hash:** bf5bb3a6e8124f0dcf21da57135d0abe
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001171843-23-000264.hdr.sgml**: 20230113

**ACCESSION NUMBER**: 0001171843-23-000264

**CONFORMED SUBMISSION TYPE**: 6-K

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20230113

**FILED AS OF DATE**: 20230113

**DATE AS OF CHANGE**: 20230113

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Forward Pharma A/S
- **CENTRAL INDEX KEY:** 0001604924
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 000000000
- **STATE OF INCORPORATION:** G7
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 6-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36686
- **FILM NUMBER:** 23529239

**BUSINESS ADDRESS:**
- **STREET 1:** OSTERGADE 24A, 1
- **CITY:** COPENHAGEN
- **STATE:** G7
- **ZIP:** 1100
- **BUSINESS PHONE:** 0114533444242

**MAIL ADDRESS:**
- **STREET 1:** OSTERGADE 24A, 1
- **CITY:** COPENHAGEN
- **STATE:** G7
- **ZIP:** 1100

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 6-K**

**REPORT OF FOREIGN PRIVATE ISSUER**

**Pursuant to Rule 13a-16 or 15d-16 of the**

**Securities Exchange Act of 1934**

January 13, 2023

**Commission File Number: 001-36686**

**Forward Pharma A/S**

**Østergade 24A, 1st Floor**

**1100 Copenhagen K, Denmark**

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

**Item 1. Receipt of Notice from Biogen**

On January 13, 2023, Forward Pharma A/S (the "Company") received notice from the two wholly owned subsidiaries of Biogen Inc. ("Biogen") party to the Settlement and License Agreement with the Company, dated January 17, 2017 (the "License Agreement"), of their exercise of the option to purchase the intellectual property outside of the United States associated with the Company (the "Designated Countries IP") pursuant to the License Agreement. The Company and Biogen have consummated the assignment of the Designated Countries IP to Biogen upon the execution of assignment agreements and the payment of a nominal amount by Biogen to FWP IP ApS, and Biogen has assumed ownership and responsibility for the assigned Designated Countries IP.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

---

| | | |
|:---|:---|:---|
|  | FORWARD PHARMA A/S | FORWARD PHARMA A/S |
| Date: January 13, 2023 | By: | /s/ Claus Bo Svendsen |
|  |  | Name: Claus Bo Svendsen |
|  |  | Title: Chief Executive Officer |

---